Literature DB >> 33385177

Conventional and Alternative Mesenchymal Stem Cell Therapies for the Treatment of Diabetes.

Lubna Rifai1, Fatima A Saleh2.   

Abstract

Diabetes is a public health problem affecting millions of people around the world. Despite the availability of many antidiabetic medications, the adequate level of control of the disease and management of diabetic patients remain a huge challenge. Because of the limitations of current therapies and the tremendous potential of non-conventional treatments such as stem cell therapy, herein, we review the applications of mesenchymal stem cells (MSCs) in treating diabetes. Owing to their unique regenerative and immunomodulatory properties, MSCs have been widely utilized in numerous applications both in animal models and human clinical trials for the treatment of diabetes. This review will summarize the latest experimental and clinical studies that have provided evidence of the beneficial role of MSCs in diabetes treatment.
© 2020. Springer Nature Switzerland AG.

Entities:  

Keywords:  Clinical trials; Diabetes; Mesenchymal stem cell; Pharmacological; Treatment

Year:  2021        PMID: 33385177     DOI: 10.1007/5584_2020_614

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  26 in total

1.  The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment.

Authors:  Fernando Ezquer; Marcelo Ezquer; David Contador; Micaela Ricca; Valeska Simon; Paulette Conget
Journal:  Stem Cells       Date:  2012-08       Impact factor: 6.277

Review 2.  Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Authors:  Catherine A Bourg; Beth Bryles Phillips
Journal:  Ann Pharmacother       Date:  2012-01-31       Impact factor: 3.154

3.  Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion.

Authors:  Jinquan Cai; Zhixian Wu; Xiumin Xu; Lianming Liao; Jin Chen; Lianghu Huang; Weizhen Wu; Fang Luo; Chenguang Wu; Alberto Pugliese; Antonello Pileggi; Camillo Ricordi; Jianming Tan
Journal:  Diabetes Care       Date:  2015-12-01       Impact factor: 19.112

Review 4.  Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

Authors:  Linda A Gallo; Ernest M Wright; Volker Vallon
Journal:  Diab Vasc Dis Res       Date:  2015-01-23       Impact factor: 3.291

5.  Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Authors:  L Blonde; M Merilainen; V Karwe; P Raskin
Journal:  Diabetes Obes Metab       Date:  2009-06       Impact factor: 6.577

6.  [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].

Authors:  P Chen; Q Huang; X J Xu; Z L Shao; L H Huang; X Z Yang; W Guo; C M Li; C Chen
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2016-05-01

7.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

8.  Hyaluronan preserves the proliferation and differentiation potentials of long-term cultured murine adipose-derived stromal cells.

Authors:  Po-Yang Chen; Lynn L H Huang; Hsyue-Jen Hsieh
Journal:  Biochem Biophys Res Commun       Date:  2007-06-08       Impact factor: 3.575

9.  Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.

Authors:  Per-Ola Carlsson; Erik Schwarcz; Olle Korsgren; Katarina Le Blanc
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

Review 10.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

Authors:  Caroline S Fox; Sherita Hill Golden; Cheryl Anderson; George A Bray; Lora E Burke; Ian H de Boer; Prakash Deedwania; Robert H Eckel; Abby G Ershow; Judith Fradkin; Silvio E Inzucchi; Mikhail Kosiborod; Robert G Nelson; Mahesh J Patel; Michael Pignone; Laurie Quinn; Philip R Schauer; Elizabeth Selvin; Dorothea K Vafiadis
Journal:  Diabetes Care       Date:  2015-08-05       Impact factor: 19.112

View more
  2 in total

Review 1.  Clinical update on the use of mesenchymal stem cells in COVID-19.

Authors:  Fatima A Saleh; Joyce Ghazzawi
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Effect of Adipose derived mesenchymal stem cells on multiple Organ Injuries in diet-induced obese mice.

Authors:  Fatima A Saleh; Hala Jaber; Ali Eid
Journal:  Tissue Barriers       Date:  2021-07-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.